The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3–4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.
DöhnerH, WeisdorfDJ, BloomfieldCD. Acute myeloid leukemia. N Engl J Med2015;373:1136–52.doi:10.1056/NEJMra1406184
2.
ArberDA, OraziA, HasserjianR, . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood2016;127:2391–405.doi:10.1182/blood-2016-03-643544
3.
KayserS, LevisMJ. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol2018;180:484–500.doi:10.1111/bjh.15032
4.
PapaemmanuilE, GerstungM, BullingerL, . Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med2016;374:2209–21.doi:10.1056/NEJMoa1516192
5.
FenauxP, MuftiGJ, Hellstrom-LindbergE, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223–32.doi:10.1016/S1470-2045(09)70003-8
6.
RobozGJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol2012;24:711–9.doi:10.1097/CCO.0b013e328358f62d
7.
SekeresMA. Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. Haematologica2008;93:1769–72.doi:10.3324/haematol.2008.000497
8.
DöhnerH, EsteyE, GrimwadeD, . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood2017;129:424–47.doi:10.1182/blood-2016-08-733196
9.
LiuY, HeP, LiuF, . Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. Mol Clin Oncol2014;2:275–81.doi:10.3892/mco.2013.222
10.
IveyA, HillsRK, SimpsonMA, . Assessment of minimal residual disease in standard-risk AML. N Engl J Med2016;374:422–33.doi:10.1056/NEJMoa1507471
11.
KayserS, LevisMJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma2014;55:243–55.doi:10.3109/10428194.2013.800198
12.
StoneRM, MandrekarSJ, SanfordBL, . Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med2017;377:454–64.doi:10.1056/NEJMoa1614359
13.
PetersdorfSH, KopeckyKJ, SlovakM, . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood2013;121:4854–60.doi:10.1182/blood-2013-01-466706
14.
BurnettAK, RussellNH, HillsRK, . Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol2012;30:3924–31.doi:10.1200/JCO.2012.42.2964
15.
BurnettAK, HillsRK, MilliganD, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol2011;29:369–77.doi:10.1200/JCO.2010.31.4310
16.
CastaigneS, PautasC, TerréC, . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet2012;379:1508–16.doi:10.1016/S0140-6736(12)60485-1
17.
HillsRK, CastaigneS, AppelbaumFR, . Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol2014;15:986–96.doi:10.1016/S1470-2045(14)70281-5
18.
TaksinAL, LegrandO, RaffouxE, . High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia2007;21:66–71.doi:10.1038/sj.leu.2404434
19.
MayerLD, HarasymTO, TardiPG, . Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther2006;5:1854–63.doi:10.1158/1535-7163.MCT-06-0118
20.
CortesJE, GoldbergSL, FeldmanEJ, . Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer2015;121:234–42.doi:10.1002/cncr.28974
21.
LancetJE, CortesJE, HoggeDE, . Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood2014;123:3239–46.doi:10.1182/blood-2013-12-540971
22.
LancetJE, GlU, CortesJE, . Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Journal of Clinical Oncology2016;34:7000.doi:10.1200/JCO.2016.34.15_suppl.7000
23.
SteinEM, DiNardoCD, PollyeaDA, . Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood2017;130:722–31.doi:10.1182/blood-2017-04-779405
24.
FathiAT, DiNardoCD, KlineI, . Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol2018.doi:10.1001/jamaoncol.2017.4695
25.
KonoplevaM, ZhaoS, HuW, . The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol2002;118:521–34.doi:10.1046/j.1365-2141.2002.03637.x
26.
KonoplevaM, PollyeaDA, PotluriJ, . Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov2016;6:1106–17.doi:10.1158/2159-8290.CD-16-0313
27.
DiNardoCD, PratzKW, LetaiA, . Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol2018;19:216–28.doi:10.1016/S1470-2045(18)30010-X
28.
PratzK, PollyeaD, JonasB, . Safety and efficacy of venetoclax (ven) in combination with decitabine or azacitidine in treatment-naive, elderly patients (≥65 years) with acute myeloid leukemia (aml). Haematologica2017:175–6.
29.
WeiA, StricklandS, RobozG, . Updated safety and efficacy results of phase 1/2 study of venetoclax plus low-dose cytarabine in treatment-naive acute myeloid leukemia patients aged>= 65 years and unfit for standard induction therapy. Haematologica2017:176.
30.
RölligC, ServeH, HüttmannA, . Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol2015;16:1691–9.doi:10.1016/S1470-2045(15)00362-9
31.
UyGL, MandrekarSJ, LaumannK, . A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv2017;1:331–40.doi:10.1182/bloodadvances.2016003053
32.
RautenbergC, NachtkampK, DienstA, . Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol2017;98:348–54.doi:10.1111/ejh.12832
33.
LevisM. Quizartinib in acute myeloid leukemia. Clin Adv Hematol Oncol2013;11:586–82013.
34.
CortesJE, PerlAE, DombretH, . nal results of a phase 2 open1label, monotherapy efficacy and safety study of quizartinib (AC220) in patients≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Am Soc Hematology2012.
35.
LevisMJ, PerlAE, DombretH, . Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (ac220) in patients with flt3-itd positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Am Soc Hematology2012.
36.
PerlAE, AltmanJK, CortesJE, . Final results of the Chrysalis trial: a first-in-human phase 1/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Am Soc Hematology2016.
37.
GalanisA, MaH, RajkhowaT, . Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood2014;123:94–100.doi:10.1182/blood-2013-10-529313
38.
RandhawaJK, KantarjianHM, BorthakurG, . Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations. Am Soc Hematology2014.
39.
WangES, TallmanMS, StoneRM, . Low relapse rate in younger patients≤ 60 years old with newly diagnosed flt3-mutated acute myeloid leukemia (aml) treated with crenolanib and cytarabine/anthracycline chemotherapy. Am Soc Hematology2017.
40.
MarcucciG, MaharryK, WuYZ, . IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2010;28:2348–55.doi:10.1200/JCO.2009.27.3730
41.
PatelKP, RavandiF, MaD, . Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol2011;135:35–45.doi:10.1309/AJCPD7NR2RMNQDVF
42.
DiNardoCD, De BottonS, SteinEM, . Ivosidenib (ag-120) in mutant idh1 aml and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. Am Soc Hematology2017.
43.
ChibaT, TanakaK. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr Protein Pept Sci2004;5:177–84.doi:10.2174/1389203043379783
44.
HershkoA. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ2005;12:1191–7.doi:10.1038/sj.cdd.4401702
45.
SwordsRT, KellyKR, SmithPG, . Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood2010;115:3796–800.doi:10.1182/blood-2009-11-254862
46.
SmithPG, TraoreT, GrossmanS, . Azacitidine/decitabine synergism with the nedd8-activating enzyme inhibitor mln4924 in pre-clinical aml models. Am Soc Hematology2011.
47.
TraoreT, MilhollenM, GrossmanS. Synergistic combination of MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE), with azacitidine, a hypomethylating agent, in pre-clinical AML cancer models. Hematologica2012;97:435.
48.
SwordsRT, WattsJ, ErbaHP, . Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J2017;7:e520.doi:10.1038/bcj.2017.1
49.
SwordsRT, CoutreS, MarisMB, . Results of a clinical study of pevonedistat (pev), a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine (aza) in older patients (pts) with acute myeloid leukemia (AML). Am Soc Hematology2016.
50.
GillS, TasianSK, RuellaM, . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood2014;123:2343–54.doi:10.1182/blood-2013-09-529537
51.
KenderianSS, RuellaM, ShestovaO, . CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia2015;29:1637–47.doi:10.1038/leu.2015.52
52.
WangQS, WangY, LvHY, . Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther2015;23:184–91.doi:10.1038/mt.2014.164
53.
TestaU, PelosiE, FrankelA. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res2014;2:4.doi:10.1186/2050-7771-2-4
54.
GlU, GodwinJ, RettigMP, . Preliminary results of a phase 1 study of flotetuzumab, a cd123 x cd3 bispecific dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Am Soc Hematology2017.
55.
PatelJP, GönenM, FigueroaME, . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med2012;366:1079–89.doi:10.1056/NEJMoa1112304
56.
De ProprisMS, RaponiS, DiverioD, . High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica2011;96:1548–51.doi:10.3324/haematol.2011.043786
57.
DiNardoCD, RavandiF, AgrestaS, . Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol2015;90:732–6.doi:10.1002/ajh.24072
58.
KornblauSM, ThallPF, EstrovZ, . The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res1999;5:1758–661999.
59.
CamposL, RouaultJP, SabidoO, . High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood1993;81:3091–61993.
60.
GrafM, HechtK, ReifS, . Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol2004;72:89–106.doi:10.1046/j.0902-4441.2003.00184.x
